Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Department of Health and Human Services
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational Ne
Funding
Award size
$1M – $10M
Award ceiling
1500000
Type
Cooperative Agreement
Dates
Deadline
Later
Posted
12/04/2024
Closes
2027-11-05
Eligibility
Eligibility
Independent school districtsNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)For profit organizations other than small businessesState governmentsPublic housing authorities/Indian housing authoritiesCounty governmentsCity or township governmentsPrivate institutions of higher educationSpecial district governmentsNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationSmall businessesNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPublic and State controlled institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)
Program
Funding area
Health - HL
Opportunity #
PAR-25-297
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov